From Optimism to Disillusion about Commitment to Transparency in the Medico-Industrial Complex

National Perinatal Epidemiology Unit. A Classified Bibliography of Controlled Trials In Perinatal Medicine 1940–1984. Oxford: Oxford University Press (for the World Health Organization), 1985

Simes R.J. Publication bias: the case for an international registry of clinical trials. J Clin Oncology 1986; 4: 1529–41

Hetherington J. , Dickersin K. , Chalmers I. , Meinert C.L. Retrospective and prospective identification of unpublished controlled trials: lessons from a survey of obstetricians and pediatricians. Pediatrics 1989; 84: 374–80

Chalmers I. Under-reporting research is scientific misconduct. JAMA 1990; 263: 1405–8

Hemminki E. Study of information submitted by drug companies to licensing authorities. BMJ 1980; 280: 833–6

Lock S. , Wells F. Preface to the second edition. In: Lock S. , Wells F. , eds. Fraud and Misconduct In Medical Research. London: BMJ Publishing Group, 1996: xi–xii

Sykes R. Being a modern pharmaceutical company. BMJ 1998; 317: 1172

Gibbs T. , Wager E. Realities of trial registration: the Glaxo Wellcome experience. Int J Pharmaceut Med 2000; 14: 203–5

Wager E. , Field E.A. , Grossman L. Good Publication Practice for pharmaceutical companies. Curr Med Res Opinion 2003; 19: 149–54

[http://www.gpp-guidelines.org]

Faculty of Pharmaceutical Medicine. Ethical Issues Working Group. Ethics in pharmaceutical medicine. Int J Pharmaceut Med 1998; 12: 193–8

Wells F. , Lunnon M.W. First Report of the Ethics Sub-Group. Society of Pharmaceutical Medicine. Int J Pharmaceut Med 2000; 14: 58–64

Melander H. , Ahlqvist-Rastad J. , Meijer G. , Beermann B. Evidence b(i)ased medicine—selective reporting from studies sponsored by pharmaceutical industry: review of studies in new drug applications. BMJ 2003; 326: 1171–3

Djulbegovic B. , Lacevic M. , Cantor A. . The uncertainty principle and industry-sponsored research. Lancet 2000; 356: 635–8

Lexchin J. , Bero L.A. , Djulbegovic B. , Clark O. Pharmaceutical industry sponsorship and research outcome and quality: systematic review. BMJ 2003; 326: 1167–70

Bhandari M. , Busse J.W. , Jackowski D. . Association between industry funding and statistically significant pro-industry findings in medical and surgical randomized trials. Can Med Assoc J 2004; 170: 477–80

Gardner W. , Lidz C.W. Failures to publish pharmaceutical clinical trials. Proceedings of The 5th International Congress On Peer Review and Biomedical Publication, Chicago, September 2005.

Yank V. , Rennie D. , Bero L. Are authors’ financial ties with pharmaceutical companies associated with positive results or conclusions in metaanalyses on antihypertensive medications? Proceedings of The 5th International Congress On Peer Review and Biomedical Publication, Chicago, September 2005.

Jørgensen A.W. , Gøtzche P. Sponsorship, bias, and methodology: Cochrane reviews compared with industry-sponsored meta-analyses of the same drugs. Proceedings of The 5th International Congress On Peer Review and Biomedical Publication, Chicago, September 2005.

Heres S. , Davis J. , Maino K. , Jetzinger E. , Kissling W. , Leucht S. Why olanzapine beats risperidone, risperidone beats quetiapine, and quetiapine beats olanzapine: an exploratory analysis of head to head comparison studies of second generation anti-psychotics. Am J Psychiat 2006; 163: 185–94

Fišter K. At the frontier of biomedical publication: Chicago 2005. BMJ 2006; 331: 838–40

Chalmers I. In the dark. Drug companies should be forced to publish all the results of clinical trials. How else can we know the truth about their products. New Scientist 6 March 2004: 19.

Pearn J. , Chalmers I. Publish and be applauded. New Scientist 6 January 1996: 40.

Herxheimer A. Open access to industry's clinically relevant data. BMJ 2004; 329: 64–5

Zarin D.A. , Tse T. , Ide N.C. Trial registration at ClinicalTrials.gov between May and October 2005. N Engl J Med 2006; 353: 2779–87

House of Commons Health Committee. The Influence of The Pharmaceutical Industry, 4th Report of Session 2004–05. London: Stationery Office, 2005

Angell M. The Truth About The Drug Companies: How They Deceive Us and What To Do About It. New York: Random House, 2004

Vandenbroucke J.P. Without new rules for industry-sponsored research, science will cease to exist. Rapid response on bmj.com, posted 14 December 2005 [http://bmj.bmjjournals.com/cgi/eletters/331/7529/1350]

Kassirer J. On The Take: How Medicine's Complicity With Big Business Can Endanger Your Health. New York: Oxford University Press, 2004

Sim I. , Chan A-W , Gülmezoğlu A.M. , Evans T. , Pang T. Clinical trial registration: transparency is the watchword. Lancet 2006; 367: 1631–3